![]() ![]() Providing GaCl 3 and containing only trace levels of the long-living mother radionuclide germanium-68 regarding 68Ga-activity, the commercially availability of generator simplified research and motivated developments with a view to a broad routine application. While only a handful clinical trials were conducted before 2012 for both radionuclides (gallium-68, 12 trials between 19 lutetium-177, 16 trials between 19) both have increasingly found application in clinical routine reflected in the rapidly increasing amount of enrolled phase 1–3 studies.Īlthough, gallium-68 was already proposed for medical use by Gleason its way to clinical application was not possible without the advancement of the primary generator design. Even more trials are enrolled for its diagnostic counterpart gallium-68 (keyword: gallium-68 268 trials ). prostate cancer (PC)), lutetium-177 is of interest, reflected in numerous clinical trials registered at (keyword: lutetium-177 87 trials ). However, not only for NETs, but also for other types of cancer (e.g. Based on the data received, the U.S. Food and Drug Administration (FDA) recently approved 177Lu-labeled DOTA-TATE for PRRT treatment. This approach allows the targeted treatment of inoperable or metastatic NETs already proven in multiple clinical trials employing radiolabeled somatostatin analogs. This concept is well established for treatment of neuroendocrine tumors (NETs) using peptide receptor radionuclide therapy (PRRT). Combining both, gallium-68 and lutetium-177, enables diagnostic molecular imaging followed by personalized treatment based on the diagnostic scan. Facilitated is this development by increasing interest in the application of its “theranostic twin” lutetium-177. Netspot gallium 68 dotatate full#NETSPOT Full U.S.In recent years, 68Ga-radiopharmaceuticals gained more and more attention due to their steadily growing clinical application. Please contact us at 95 for further details. This product has been designated as an orphan drug by the EMA and the FDA. NETSPOT™ is a novel patented kit developed by AAA for the preparation of gallium Ga 68 dotatate for injection, for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients using Positron Emission Tomography (“PET“). NETSPOT™ is a significant improvement over existing diagnostic tools and will enable us to more accurately stage and better manage patients. In a clinical study, NETSPOT™ demonstrated the ability to change management decisions regarding patients in 71% of cases previously imaged with Octreoscan. Saving just one patient from futile surgery can improve the treatment experience overall and significantly reduce the cost of care by reducing repetitive, often frustrating, and limitless diagnostics. NETSPOT™ offers superior sensitivity and accuracy compared to previously available diagnostics for NET patients. Gallium PET/CT also allows for calculation of standardized uptake value, has less whole body radiation, and is performed in less time versus Octreoscan. Gallium PET/CT is more accurate for staging and superior to Octreoscan SPECT in the detection of overall number of lesions in the body as well as organs and bones. Use of NETSPOT changed patient treatment and management in 71% of patients due to greater specificity compared to Octreoscan. It is a form of octreotide, which binds to a receptor on many NETs called the Somatostatin Receptor. NETSPOT, the new tracer for Gallium 68-Dotatate scan, is the next generation of OCTREOSCAN. PET Imaging Institute of South Florida is proud to offer newly available NETSPOT (Gallium 68-Dotatate) scan: A novel PET/CT tracer for the detection of Neuro Endocrine Tumors (NETs) ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |